Sugi Predict

Sugi Predict / Compounds / SCHEMBL8744287

SCHEMBL8744287

SCHEMBL8744287

Nc1ccc(CO)c([N+](=O)[O-])c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ ALDH1A1 P00352 5/20 0.58
▸ TDP1 Q9NUW8 4/20 0.58
▸ CYP3A4 P08684 2/20 0.58
▸ TSHR P16473 3/20 0.55
▸ RECQL P46063 1/20 0.55
▸ CYP1A2 P05177 1/20 0.44
▸ SNCA P37840 2/20 0.43
▸ MEN1 O00255 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ PDK1 Q15118 1/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ PDE7A Q13946 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8447360 0.87 ALOX15 (0.58) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL38658431 0.86 ALDH1A1 (0.64) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
Hydrogen Sulfide SCHEMBL28060660 0.86 ALOX15 (0.56) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
Methane SCHEMBL27666967 0.86 ALOX15 (0.56) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL2766494 0.85 TDP1 (0.58) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL2768561 0.85 TDP1 (0.58) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL29389163 0.85 ALDH1A1 (0.62) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL1351968 0.85 ALDH1A1 (0.62) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL358991 0.83 ALDH1A1 (0.61) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1
SCHEMBL7218334 0.83 ALDH1A1 (0.60) ALOX15L3MBTL1MAPK1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117890453-A Method for detecting bioactive peptide containing primary amino based on small molecular mass spectrometry probe 苏州南医大创新中心 2024-04-16 — — CN claimed
US-20260061065-A1 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2026-03-05 — — US disclosed
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2025-12-25 — — US disclosed
WO-2025111431-A1 ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF LES LABORATOIRES SERVIER (FR) 2025-05-30 — — WO disclosed
EP-4525927-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF Novartis AG (CH) 2025-03-26 — — EP disclosed
EP-4525928-A1 ANTIBODY DRUG CONJUGATES Novartis AG (CH) 2025-03-26 — — EP disclosed
CN-119613486-A Antibody drug conjugates with linkers comprising hydrophilic groups 诺华股份有限公司 2025-03-14 — — CN disclosed
CN-119613487-A Antibody drug conjugates with linkers comprising hydrophilic groups 诺华股份有限公司 2025-03-14 — — CN disclosed
CN-113853219-B Antibody drug conjugates with linkers comprising hydrophilic groups 诺华股份有限公司 2025-01-07 — — CN disclosed
CN-117890453-A Method for detecting bioactive peptide containing primary amino based on small molecular mass spectrometry probe 苏州南医大创新中心 2024-04-16 — — CN disclosed
CN-1030739-C Method for selectively coating metal surface, method for forming circuit pattern from metal surface and photosensitive emulsion used therefor GRACE W R & CO (US) 1996-01-17 — — CN disclosed
EP-0468002-A4 AUTODEPOSITION EMULSION FOR SELECTIVELY PROTECTING METALLIC SURFACES GRACE W R & CO (US) 1995-08-09 — — EP disclosed
US-5232815-A Corrosion resistance W. R. GRACE & CO.-CONN. (US) 1993-08-03 — — US disclosed
EP-0518453-A1 A method of making electrical circuit traces W.R. Grace & Co.-Conn. (US) 1992-12-16 — — EP disclosed
EP-0468002-A1 AUTODEPOSITION EMULSION FOR SELECTIVELY PROTECTING METALLIC SURFACES W.R. GRACE & CO.-CONN. (US) 1992-01-29 — — EP disclosed
CN-1054836-A Automatic deposition emulsion and the method for the metal surface being carried out selective protection with this emulsion GRACE W R & CO (US) 1991-09-25 — — CN disclosed
WO-1991008840-A1 AUTODEPOSITION EMULSION FOR SELECTIVELY PROTECTING METALLIC SURFACES W.R. GRACE & CO.-CONN. (US) 1991-06-27 — — WO disclosed
US-4808682-A BLEND WITH OLEFINICALLY UNSATURATED SILICON COMPOUND BASF AKTIENGESELLSCHAFT (DE) 1989-02-28 — — US disclosed
US-4632900-A Process for the production of images after electrodeposition of positive photoresist on electrically conductive surface CIBA-GEIGY CORPORATION (US) 1986-12-30 — — US disclosed
EP-0155231-A2 Image-producing process CIBA-GEIGY AG (CH) 1985-09-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF BID, BCL2, MCL1 ALOX15 4791/4885L3MBTL1 1429/4885MAPK1 3051/4885
US-20260061065-A1 ANTIBODY DRUG CONJUGATES FCGR2A, FCGR3B, BCL3 ALOX15 3629/4885L3MBTL1 264/4885MAPK1 2112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.